Treatment of relapsed and refractory Hodgkin Lymphoma

Bastian von Tresckow, Craig Moskowitz

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%–20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody–drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies.

Original languageEnglish (US)
Pages (from-to)180-185
Number of pages6
JournalSeminars in Hematology
Volume53
Issue number3
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Hodgkin Disease
Transplants
Stem Cells
Therapeutics
Drug Therapy
Recurrence
Standard of Care
Palliative Care
Antibodies

Keywords

  • Autologous stem cell transplant
  • Brentuximab vedotin
  • High-dose chemotherapy
  • Hodgkin lymphoma
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of relapsed and refractory Hodgkin Lymphoma. / von Tresckow, Bastian; Moskowitz, Craig.

In: Seminars in Hematology, Vol. 53, No. 3, 01.07.2016, p. 180-185.

Research output: Contribution to journalReview article

von Tresckow, Bastian ; Moskowitz, Craig. / Treatment of relapsed and refractory Hodgkin Lymphoma. In: Seminars in Hematology. 2016 ; Vol. 53, No. 3. pp. 180-185.
@article{df79f307005c46cd845911b5c581b3d9,
title = "Treatment of relapsed and refractory Hodgkin Lymphoma",
abstract = "Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10{\%}–20{\%} of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50{\%}. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody–drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies.",
keywords = "Autologous stem cell transplant, Brentuximab vedotin, High-dose chemotherapy, Hodgkin lymphoma, Relapse",
author = "{von Tresckow}, Bastian and Craig Moskowitz",
year = "2016",
month = "7",
day = "1",
doi = "10.1053/j.seminhematol.2016.05.010",
language = "English (US)",
volume = "53",
pages = "180--185",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Treatment of relapsed and refractory Hodgkin Lymphoma

AU - von Tresckow, Bastian

AU - Moskowitz, Craig

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%–20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody–drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies.

AB - Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%–20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. The anti-CD30 antibody–drug conjugate brentuximab vedotin (BV) has been shown to induce high response rates in these patients; however, durable responses were reported in a small percentage of patients only. For carefully selected patients with multiple relapses, dose-reduced allogeneic transplant (RICallo) is a potentially curative option. The role of RICallo will have to be re-evaluated in the era of anti-programmed death-1 (PD1) antibodies.

KW - Autologous stem cell transplant

KW - Brentuximab vedotin

KW - High-dose chemotherapy

KW - Hodgkin lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84991207995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991207995&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2016.05.010

DO - 10.1053/j.seminhematol.2016.05.010

M3 - Review article

C2 - 27496309

AN - SCOPUS:84991207995

VL - 53

SP - 180

EP - 185

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -